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Peter J. Sadler*
 
Department of Chemistry, University of Warwick, Gibbet Hill Road, Coventry CV4 
7AL, U.K.  
 
Abstract: Replacing the N,N-chelating ligand 2,2′-bipyridine (bpy) in the IrIII 
pentamethylcyclopentadienyl (Cp*) complex [(η5-C5Me5)Ir(bpy)Cl]
+
 (1) with the 
C,N-chelating ligand 2-phenylpyridine (phpy) to give [(η5-C5Me5)Ir(phpy)Cl] (2) 
switches on cytotoxicity towards A2780 human ovarian cancer cells (IC50 values 
of >100 μM for 1 and 10.8 μM for 2). Ir–Cl hydrolysis is rapid for both complexes 
(hydrolysis equilibrium reached in < 5 min at 278 K). Complex 2 forms adducts with 
both 9-ethylguanine (9-EtG) and 9-methyladenine (9-MeA), but preferentially with 
9-EtG when in competition (ca. 85% of total Ir after 24 h). The X-ray crystal structure 
of [(η5-C5Me5)Ir(phpy)(9-EtG-N7)]NO3·1.5CH2Cl2 confirms N7 binding to guanine. 
2D NMR spectra show that complex 2 binds to adenine mainly through N1, consistent 
with DFT calculations. DFT calculations indicate an interaction between the nitrogen 
of the NH2 group (9-MeA) and carbons from phpy in the adenine adduct of complex 2. 
Calculations show that the most stable geometry of the adduct 
[(η5-C5Me5)Ir(phpy)(9-EtG-N7)]
+
 (3b), has the C6O of 9-EtG orientated towards the 
pyridine ring of phpy, and for [(η5-C5Me5)Ir(phpy)(9-MeA-N1)]
+ 
(4(N1)a), the NH2 
group of 9-EtA is adjacent to the phenyl ring side of phpy. Complex 2 is more 
hydrophobic than complex 1, with log P values of 1.57 and –0.95, respectively. The 
strong nucleobase binding and high hydrophobicity of complex 2 probably contribute 
to its promising anticancer activity.  
*To whom correspondence should be addressed. E-mail: P.J.Sadler@warwick.ac.uk. 
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Introduction 
Organometallic complexes offer rich versatility for the design of anticancer agents.
1
 
Iridium complexes are best known for their inertness,
2
 and indeed inert 
organometallic Ir
III
 scaffolds are finding use as potent enzyme inhibitors.
3
 The 
half-sandwich fragment {Cp*Ir
III
} (Cp* = pentamethylcyclopentadienyl) has been 
used as a stabilizing entity in many organometallic iridium complexes.
4
 By suitable 
choice of the other ligands, relatively reactive Cp* Ir
III
 complexes can be designed.
5
 
Here we focus attention on the role of the XY chelating ligand in 
[(η5-C5Me5)Ir(XY)Cl]
0/n+
 complexes. Chelating ligands are already known to have a 
major influence on the DNA base specificity and cytotoxicity of organometallic 
half-sandwich complexes of the type [(η6-arene)Ru/Os(XY)Z].6 In a recent study we 
have shown that Cp* Ir
III
 complexes with XY = N,N-bound ethylenediamine, 
2,2′-bipyridine, and 1,10-phenanthroline, or N,O-bound picolinate, are all inactive and 
non-cytotoxic towards A2780 human ovarian cancer cells with IC50 values 
(concentrations at which 50% of the cell growth is inhibited) all > 100 μM.5 Also Cp* 
PTA iridium(III) complexes (PTA = 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane),
7
 
and Cp* pyTz iridium(III) complexes (pyTz = 2-(pyridine-2-yl)thiazole),
8
 are 
reported to be inactive against A2780 cells (IC50 values > 300 μM). Sheldrick et al. 
have shown that activity can be switched on by incorporating a DNA intercalator 
(N,N-chelating polypyridyl ligand) into some Cp* Ir
III
 complexes.
9
 Here we introduce 
a different switch involving a single atom change (C− for N) in a chelating 
2,2′-bipyridine ligand to afford a neutral complex. 
Cyclometallated organometallic complexes incorporating C,N-chelating ligands 
have attracted much attention because of their wide applications in both catalysis and 
luminescence.
10
 However, few such previous studies have involved their anticancer 
activity.
11
 In the work reported here, we compare the structure, reactivity and cancer 
cell cytotoxicity of Cp* Ir
III
 complexes containing a neutral N,N-bound 
2,2′-bipyridine (bpy) chelating ligand and an anionic C,N-bound 2-phenylpyridine 
 3 
 
(phpy) ligand. We have studied the hydrolysis, nucleobase binding, and 
hydrophobicity (octanol/water partition), and attempted to relate these to their activity 
towards A2780 ovarian cancer cells. This appears to be the first report of an active Ir
III
 
anticancer complex containing both Cp* and a C,N-chelating ligand. This class of 
iridium complexes is attractive for development as new anticancer agents. 
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Chart 1. Iridium(III) Pentamethylcyclopentadienyl Complexes Studied in This Work. Complex 1 
Is Isolated as Cl
−
 Salt, Complexes 3, 4(N1) and 4(N7) as NO3
−
 Salts. 
 
Experimental Section 
Materials. IrCl3·nH2O, 9-ethylguanine (9-EtG), 9-methyladenine (9-MeA), 
2,2′-bipyridine, 2-phenylpyridine, octan-1-ol (≥ 99%), and NaCl (> 99.999%) were 
purchased from Sigma-Aldrich. Nitric acid (72%) from Sigma Aldrich was double 
distilled and diluted using double de-ionized water. Complexes 
[(η5-C5Me5)Ir(bpy)Cl]Cl (1)
4a
 and [(η5-C5Me5)Ir(phpy)Cl] (2)
12
 were prepared 
according to literature methods. Details of the synthesis and characterization of 
complex [(η5-C5Me5)Ir(phpy)(9-EtG-N7)]NO3 (3·NO3) are in the Supporting 
Information.  
X-ray crystallography. Diffraction data for 3·NO3·1.5CH2Cl2 were obtained on an 
Oxford Diffraction Gemini four-circle system with a Ruby CCD area detector using 
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Mo Kα radiation. Absorption corrections were applied using ABSPACK.13 The 
crystals were mounted in oil and held at 100(2) K with the Oxford Cryosystem Cobra. 
The structures were solved by direct methods using SHELXS (TREF)
14
 with 
additional light atoms found by Fourier methods. Complexes were refined against F
2
 
using SHELXL,
15
 and hydrogen atoms were added at calculated positions and refined 
riding on their parent atoms.  
Crystallographic data are shown in Table S1, and selected bond lengths and angles 
are listed in Table S2. There is one CH2Cl2 molecule in a general position in the cell 
and one CH2Cl2 molecule that straddles a cell face. X-ray crystallographic data for 
3·NO3·1.5CH2Cl2 are available as Supporting Information and have been deposited in 
the Cambridge Crystallographic Data Centre under the accession number CCDC 
816981. 
NMR Spectroscopy. 
1
H NMR spectra were acquired in 5 mm NMR tubes at 310 K 
(unless stated otherwise) on either Bruker DPX 400 (
1
H = 400.03 MHz) or AVA 600 
(
1
H = 600.13 MHz) spectrometers. 
1
H NMR chemical shifts were internally 
referenced to CHD2OD (3.33 ppm) for methanol-d4 or to 1,4-dioxane (3.75 ppm) for 
aqueous solutions. All data processing was carried out using XWIN-NMR version 3.6 
(Bruker UK Ltd.). 
Mass Spectrometry. Electrospray ionization mass spectra (ESI-MS) were obtained 
by infusing the samples into a Bruker Esquire 2000 mass spectrometer. The mass 
spectra were recorded with a scan range of m/z 50–1000 for positive ions.  
Elemental Analysis. CHN elemental analyses were carried out on a CE-440 
elemental analyzer by Exeter Analytical (UK) Ltd. 
Computational Details. The Gaussian 03 package
16
 was employed for all 
calculations. Geometry optimization calculations for complexes 1 and 2, their aqua 
derivatives and their 9-ethylguanine (9-EtG) and 9-ethyladenine (9-EtA) adducts were 
performed in the gas phase with the gradient-corrected correlation functional PBE0.
17
 
9-EtA was chosen instead of 9-MeA (used in experimental work) for the sake of 
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comparison in the DFT work. The LanL2DZ basis set and effective core potential
18
 
were used for the Ir atom and the 6-31G** basis set was used for all other atoms.
19
 
The nature of all stationary points was confirmed by performing a normal-mode 
analysis. Electrostatic potential surfaces (EPSs) for complexes 1 and 2, their aqua 
derivatives and their 9-EtG and 9-EtA adducts were calculated and mapped on 
electron density (isovalue 0.04) of the molecules. The electrostatic potential is 
represented with a color scale ranging from red (–0.500 au) to blue (0.500 au). DFT 
results are summarized in the Supporting Information section. 
Interactions with Nucleobases. The reaction of complexes 1 and 2 (ca. 1 mM) 
with nucleobases typically involved addition of a solution containing one mol equiv 
of nucleobase in D2O to an equilibrium solution of complexes 1 and 2 in 10% 
MeOD-d4/90% D2O (v/v). The pH* value (pH meter reading without correction for 
effects of deuterium on the glass electrode) of the sample was adjusted if necessary so 
as to remain close to 7.4 (physiological). The reaction of equimolar amounts of 
complex 1 with 9-MeA was carried out in MeOD-d4 (ca. 7 mM) to provide 
concentrations high enough for the 2D NMR work. 
1
H NMR spectra, 2D 
1
H–1H 
TOCSY and NOESY of these solutions were recorded at 310 K after various time 
intervals. 
Formation constants for nucleobase complexes, K = [bound 9-EtG or 9-MeA][free 
Cl
–
]/[free 9-EtG or 9-MeA][free iridium complex], are based on NMR peak integrals.  
ICP-MS Instrumentation and Calibration. All ICP-MS analyses were carried 
out on an Agilent Technologies 7500 series ICP-MS instrument. The water used for 
ICP-MS analysis was doubly de-ionized (DDW) using a Millipore Milli-Q water 
purification system and a USF Elga UHQ water deionizer. The iridium Specpure 
plasma standard (Alfa Aesar, 1000 ppm in 10% HCl) was diluted with 3% HNO3 
DDW to freshly prepare calibrants at concentrations 1000, 800, 400, 200, 100, 50, 10, 
1 and 0.1 ppb. The ICP-MS instrument was set to detect 
193
Ir with a typical detection 
limit of ca. 8 ppt using no-gas mode. 
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log P Determination. Octanol-saturated water (OSW) and water-saturated octanol 
(WSO) were prepared using analytical grade octanol and 0.2 M NaCl aqueous 
solution (to suppress hydrolysis of the chlorido complexes). Aliquots of stock 
solutions of iridium complexes in OSW were added to equal volumes of WSO and 
shaken in an IKA Vibrax VXC basic shaker for 4 h at 500 g/min to allow partition at 
ambient temperature (∼298 K). The aqueous layer was carefully separated from the 
octanol layer for iridium analysis. 
193
Ir was quantified from aliquots taken from the 
octanol-saturated aqueous samples before and after partition. Partition coefficients of 
Ir
III
 complexes were calculated using the equation log P = log ([Ir]WSO/[Ir]OSW), where 
[Ir]WSO was obtained by subtraction of the Ir content of the aqueous layer after 
partition from the Ir content of the aqueous layer before partition. 
Cytotoxicity. The A2780 ovarian cell line was obtained from the ECACC 
(European Collection of Animal Cell Culture, Salisbury, UK). The cells were 
maintained in RPMI 1640 media (supplemented with 10% foetal calf serum 1% 
L-glutamine, and 1% penicillin/streptomycin). All cells were grown at 310 K in a 
humidified atmosphere containing 5% CO2. Stock solutions of the Ir
III
 complexes 
were firstly prepared in DMSO to assist dissolution (maximum final DMSO 
concentration 1.25%), and then diluted into 0.9% saline and medium (1:1). After 
plating 5000 A2780 cells per well on day 1, Ir
III
 complexes were added to the cancer 
cells on day 3 at concentrations ranging from 0.5 μM to 100 μM. Cells were exposed 
to the complexes for 24 h, washed with PBS, supplied with fresh medium, allowed to 
grow for three doubling times (72 h), and then the protein content (proportional to cell 
survival) measured using the sulforhodamine B (SRB) assay.
20
 The standard errors are 
based on two independent experiments carried out in triplicate. 
 
Results and Discussion 
We have investigated the chemical reactivity and cancer cell cytotoxicity of the 
isoelectronic complexes [(η5-C5Me5)Ir(bpy)Cl]
+
 (1) and [(η5-C5Me5)Ir(phpy)Cl] (2), 
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which contain 2,2′-bipyridine and 2-phenylpyridine as N,N- and C,N-chelating 
ligands, respectively (Chart 1), including hydrolysis, nucleobase binding and DFT 
calculations. The syntheses and X-ray structures of both complexes have been 
reported previously.
4a,12
 
Structural and Electronic Differences between Complexes 1 and 2. There is a 
change in the charge when replacing complex 1 (positively-charged) containing 
N,N-bound 2,2′-bipyridine by complex 2 (neutral) containing C,N-bound 
2-phenylpyridine. Geometry optimization calculations for complexes 1 and 2 were 
performed using the PBE0 functional. Selected bond distances for 
[(η5-C5Me5)Ir(bpy)Cl]
+
 (1) and [(η5-C5Me5)Ir(phpy)Cl] (2) are listed in Table 1 and 
are in good agreement with the reported X-ray crystal structures.
4a,12
 In complex 2, the 
chelating ligand is closer to the Ir
III
 center than in complex 1; a short Ir–C(phenyl) 
distance causes elongation of the Ir–Cl bond as well as the Ir–Cp*(centroid) distance 
(Table 1). The same features are observed for the aqua adducts of complexes 1 and 2 
(Table S3), and their 9-EtG and 9-EtA adducts (Tables S4 and S5, respectively). 
 
Table 1. Selected Bond Distances for [(η
5
-C5Me5)Ir(bpy)Cl]
+
 (1) and [(η
5
-C5Me5)Ir(phpy)Cl] (2) 
Calculated at the PBE1PBE/LANLD2Z/6-31G** Level 
Complex Ir–Cl Ir–N1/C1 Ir–N2 Ir–Centroid 
1 2.398 2.083 2.083 1.816 
2 2.411 2.009 2.077 1.863 
1 (X-ray)
4a
 2.404(2) 2.076(8) 2.090(9) 1.786 
2 (X-ray)
12
 2.3968(7) 2.046(2) 2.080(2) 1.820 
 
Details of the frontier orbitals and electrostatic potential surfaces (EPSs) of 
complexes 1 and 2, their aqua adducts, and their 9-EtG and 9-EtA adducts are in the 
Supporting Information (Table S6, S7, S8 and Figure S1). No significant differences 
or unexpected features are observed for the frontier orbitals of these derivatives or for 
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their EPSs.  
Hydrolysis. Hydrolysis of M−Cl bonds is often an activation step for transition 
metal anticancer complexes.
21
 We have previously reported that complex 1 undergoes 
rapid hydrolysis.
5
 The hydrolysis of complex 2 (1 mM) in 10% MeOD-d4/90% D2O 
(v/v) was studied by 
1
H NMR spectroscopy. The presence of methanol ensured 
sufficient solubility of the complex. Complex 2 underwent fast hydrolysis even at 278 
K. The comparison for the hydrolysis rate of complexes 1 and 2 could not be 
determined since the hydrolysis equilibrium was reached by the time the first 
1
H 
NMR spectrum was acquired (~ 5 min). At equilibrium ca. 32% of complex 2 are in 
the hydrolyzed form. To confirm the hydrolysis of 2, NaCl was added to an 
equilibrium solution containing the chlorido complex 2 and its aqua adduct 2_D2O 
(Figure 1A) to give concentrations of 4, 23 and 104 mM NaCl, mimicking the 
chloride concentrations in cell nucleus, cell cytoplasm and blood plasma, 
respectively.
22
 
1
H NMR spectra were then recorded within 10 min of the additions at 
298 K. With addition of NaCl, 
1
H NMR peaks corresponding to the chlorido complex 
2 increased in intensity whilst peaks for the aqua adduct 2_D2O decreased in intensity, 
Figure 1B. These data confirm the formation of the aqua adduct and the reversibility 
of the process. On the basis of 
1
H NMR peak integrals, almost no hydrolyzed complex 
2 was found to be present in 104 mM [Cl−] or in 23 mM [Cl−], and < 5% of aqua 
complex 2_D2O was observed at 4 mM [Cl
−] after 10 min with no further change after 
24 h. Therefore hydrolysis is readily suppressed by NaCl, even at a chloride 
concentration close to that of the cell nucleus.  
The fast hydrolysis can be related to the presence of the five methyl groups on the 
Cp ring as strong electron donors which increase the electron density on the Ir center 
and facilitate chloride loss. A similar hydrolysis behavior was observed for complex 
1
5
 and for some hexamethylbenzene Ru
II
 complexes (compared to unsubstituted 
benzene complexes).
23
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Figure 1. Hydrolysis of [(η
5
-C5Me5)Ir(phpy)Cl] (2). Low field region of the 
1
H NMR spectrum of 
(A) an equilibrium solution of 2 (1 mM) in 10% MeOD-d4/90% D2O (v/v) at 298 K, and (B) 10 
min after addition of NaCl (4 mM). The peaks for the chlorido complex 2 increased in intensity 
while peaks for the aqua complex [(η
5
-C5Me5)Ir(phpy)(D2O)]
+
 (2_D2O) decreased upon addition 
of NaCl. 
 
Interactions with Nucleobases. Since binding to DNA is often associated with the 
cytotoxic activity of metal anticancer drugs,
24
 reactions of complex 2 (1 mM) in 10% 
MeOD-d4/90% D2O (pH* = 7.4) at 310 K with 1 mol equiv of the nucleobases 
9-ethylguanine (9-EtG) and 9-methyladenine (9-MeA) were investigated. The extent 
of nucleobase adduct formation and relative formation constant for complexes 1 and 2 
based on 
1
H NMR peak integrals are shown in Table 2.  
 
Table 2 Formation Constants for 9-EtG and 9-MeA Adducts of Complexes 1 (1 mM) and 2 (1 
mM) at 310 K after 24 h (in 90% D2O/10% MeOD-d4), log P values, and IC50 Values for A2780 
Human OvarianCancer Cell Line for Complexes 1 and 2  
Complex 
 9-EtG 
adduct  
  9-MeA 
adduct  
log P A2780
ab
 
 %   K %    K  IC50 (μM) 
1 61
c
  1.6 0
c
 −0.95 ± 0.06 >100
c
 
2 96   230.4 86   6.1 1.57 ± 0.08 10.8 ± 1.7 
a 
Cisplatin IC50 as control 1.2±0.1 μM. 
b 
Drug-treatment period was 24 h. 
c
 Ref. 5 
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Addition of 1 mol equiv of 9-EtG to an equilibrium solution of complex 2 resulted 
in 96% formation of the G adduct, [(η5-C5Me5)Ir(phpy)(9-EtG)]
+
 (3). The 
1
H NMR 
spectrum of the reaction mixture in 10% MeOD-d4/90% D2O at 310 K showed a new 
9-EtG H8 peak at 7.46 ppm, shifted by 0.37 ppm to high field relative to that of free 
9-EtG. ESI-MS studies on the diluted sample (0.2 mM) gave a major peak at m/z 
661.2, Figure S2, consistent with the presence of [(η5-C5Me5)Ir(phpy)(9-EtG)]
+
 (calcd 
m/z 661.1). The formation constant K for the 9-EtG adduct of complex 2 is ca. 144 
times that of complex 1. 
The 9-EtG adduct of complex 2, [(η5-C5Me5)Ir(phpy)(9-EtG)]NO3 3·NO3 was 
isolated, and the X-ray crystal structure determined, which confirmed that 9-EtG is 
bound through N7 (Figure 2A). The nitrate counter ion shows H-bonding to a 9-EtG 
ligand, with distances of 1.987(19) Å (O12∙∙∙H26) and 1.975(19) Å (O10∙∙∙H27A), 
Figure 2B and Table S9. The H-bonded chains are linked by two hydrogen bonds 
N27−H27B∙∙∙N28 (2.105(19) Å) between two symmetrical guanines. From a search 
of the Cambridge Database, this appears to be the first example of a X-ray structure of 
a guanine adduct containing a chiral iridium center. 
 
 
 
 
 
 
Figure 2. X-ray crystal structure of [(η
5
-C5Me5)Ir(phpy)(9-EtG-N7)]NO3·1.5CH2Cl2 
(3·NO3·1.5CH2Cl2). (A) Atom numbering scheme. Only the cation and anion are shown for clarity. 
(B) Formation of dimers linked by hydrogen bonding of neighboring N27H and N28 atoms of 
9-EtG, where N27−H27B∙∙∙N28 (2.105(19) Å). The NO3
−
 counter anions form H-bonds with 
N26H and N27H, where O12∙∙∙H26 is 1.987(19) Å and O10∙∙∙H27A is 1.975(19) Å. 
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Addition of 1 mol equiv of 9-MeA to an equilibrium solution of complex 2 in 10% 
MeOD-d4/90% D2O at 310 K resulted in ca. 86% of 2 reacting with 9-MeA after 24 h. 
Two adenine nucleobase adducts are formed in a 4.5:1 ratio as analyzed by 
1
H NMR, 
and correspond to iridium binding to N1 and N7 of adenine, 4(N1) and 4(N7), Chart 1. 
ESI-MS studies on the diluted sample (0.2 mM) gave a major peak at m/z 631.2, 
Figure S3, consistent with the formation of [(η5-C5Me5)Ir(phpy)(9-MeA)]
+
 (calcd m/z 
631.0). 
To understand the mode of biding to adenine, 1:1 mol equiv of 9-MeA and complex 
2 were dissolved in MeOD-d4 (7 mM), and 2D 
1
H–1H TOCSY (Figure 3) and 
NOESY spectra were recorded (Figure 4). Only 40% of complex 2 reacted with 
9-MeA in MeOD-d4 at 310 K after 24 h, which indicates that nucleobase binding in 
MeOD-d4 was less favorable than in 10% MeOD-d4/90% D2O (86%, Table 2). This 
may be due to the poor solvation of the leaving chloride by MeOD-d4 and lack of 
hydrolysis. Complex 2 also formed two 9-MeA adducts in a 6.6:1 ratio in MeOD-d4 
based on the integration of the Cp* 
1
H NMR peaks. The 
1
H NMR peaks of the minor 
adduct in the low field region are weak and overlapped by the peaks of the major 
adduct, Figure 3. An NOE cross-peak between H2 of 9-MeA and the HC=N proton of 
phpy was observed (Figure 4), suggesting that coordination of 9-MeA through N1 is 
the major binding mode. This result is consistent with the DFT calculations which 
show that [(η5-C5Me5)Ir(phpy)(9-EtA-N1)]
+
 is more stable than 
[(η5-C5Me5)Ir(phpy)(9-EtA-N7)]
+
 by 18.36 kJ/mol (Table S5). 
The N7 atoms of G and A are accessible to metals, such as Pt in cisplatin,
25
 for 
coordination in the major groove of DNA, whereas N1 of A is involved in 
Watson-Crick base-pairing. Complex 2 reacted with guanine via N7, and formed 
adenine adducts via N1 and N7, with 4(N1) being the major adenine adduct. In 
addition, complex 2 has a higher affinity for guanine compared to adenine. Binding to 
guanine may therefore play a more significant role in its cytotoxicity. 
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Figure 3. 
1
H–
1
H TOCSY 2D NMR spectrum of an equimolar equilibrium solution of of 9-MeA 
and complex 1 (7 mM) in MeOD-d4. Peak assignments are indicated on the structures. 
 
 
 
 
 
 
 
 
 
Figure 4. Model and 2D NOESY spectrum of [(η
5
-C5Me5)Ir(phpy)(9-EtA-N1)]
+
. (A) Optimized 
geometry showing a short distance of 2.275 Å between HC=N proton of phpy ( ) and H2 of 
bound 9-MeA ( ); (B) 
1
H–
1
H NOESY 2D NMR spectrum of adduct in the reaction mixture of 
complex 2 [(η
5
-C5Me5)Ir(phpy)Cl] with 1 mol equiv of 9-MeA (7 mM, MeOD-d4), which 
confirms coordination of 9-MeA through N1 as the major binding mode. 
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Compared with the C,N-chelated 2-phenylpyridine complex 2, which binds 
significantly to both nucleobases, the N,N-chelated 2,2′-bipyridine complex 1 formed 
an adduct only with 9-EtG (61%), and not with 9-MeA after 24 h (Table 2), indicating 
weaker binding to both guanine and adenine bases.  
 
 
 
 
 
 
 
 
Figure 5. (A) DFT optimized structure of complex [(η
5
-C5Me5)Ir(phpy)(9-EtA-N1)]
+
. (B) 
HOMO–2 orbital for the DFT-optimized complex [(η
5
-C5Me5)Ir(phpy)(9-EtA-N1)]
+
 showing the 
N(NH2 of 9-EtA)∙∙∙C1/C2(phpy) interactions. 
 
The calculations suggest that there is a π orbital interaction between N(NH2 of 
adenine) and C1 and C2(phpy) for the DFT-optimized complex 
[(η5-C5Me5)Ir(phpy)(9-EtA-N1)]
+
, Figure 5. This may explain the formation of 
adenine adducts [(η5-C5Me5)Ir(phpy)(9-MeA)]
+
 by complex 2. These 
negatively-charged carbons on the phenyl ring appear to be favored for such 
interactions compared with the analogous atoms in the pyridine ring where C1 is 
positively charged and C2 is slightly negative. Although complex 2 can form 9-MeA 
adducts in MeOD-d4 and D2O, which may be due to the influence of water on the 
stability of different tautomeric forms of DNA bases through hydrogen bonding 
interactions,
26
 the adducts readily dissociate in CDCl3, acetone-d6, DMSO-d6, and 
THF-d8, indicating that they are relatively unstable in these solvents. The formation 
constant for the 9-MeA adduct (K = 6.1, in 90% D2O/10% MeOD-d4, Table 2), is ca. 
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38 times smaller than that of the 9-EtG adduct. Competition between equal molar 
amounts of 9-EtG and 9-MeA for complex 2 (0.4 mM) in 10% MeOD-d4/90% D2O at 
310 K (pH* = 7.4) gave rise to the 9-EtG adduct as the major product (ca. 85%) after 
24 h, confirming the higher affinity for the nucleobase 9-EtG.  
Some Ru
II
 and Ir
III
 complexes containing N,N-chelating ligands such as 
ethylenediamine and 1,10-phenanthroline have little affinity for adenine residues.
5,27
 
In contrast, organometallic complexes containing N,O-chelating ligands or 
O,O-chelating ligands such as picolinate and acetylacetonate bind to both guanine and 
adenine residues.
5,6c,28
 However, some Os
II
 complexes containing picolinate 
derivatives show a strong preference for adenine.
29
 The chelating ligands in these 
complexes appear to play an important role in the recognition of nucleobases, 
interacting especially with the C6O of guanine or the C6NH2 of adenine, which can 
be rationalized in terms of H-bonding, non-bonding repulsive interactions between the 
chelating ligand and nucleobase substituents, and the electronic properties of the 
various nucleobase coordination sites.
30
 The chelating ligands in the present work also 
have a significant effect on the selectivity of nucleobase binding. Complex 1 
containing N,N-chelating 2,2′-bipyridine reacted only with 9-EtG, whilst complex 2 
containing C,N-chelating 2-phenylpyridine formed both 9-EtG and 9-MeA adducts, 
preferentially binding to 9-EtG when in competition, which may result from the steric 
hindrance of the NH2 group at the 6-position of the adenine ring. Some Pt
II
 antitumor 
complexes bearing C,N-chelating ligands also show strong binding to 9-EtG.
31
 
Configurational Studies of G and A adducts. We investigated the relative 
stabilities of isomers of the guanine and adenine adducts. For 
[(η5-C5Me5)Ir(phpy)(9-EtG-N7)]
+
 (3) two orientations of the carbonyl group with 
respect to the 2-phenylpyridine ring are possible. In 3a the carbonyl group of 9-EtG is 
orientated towards the phenyl ring of the phpy ligand, and in 3b the carbonyl group is 
on the pyridine side. In the crystal studied by X-ray diffraction, the complex adopts 
configuration 3b (Figure 3A), with a NC–H∙∙∙O6(EtG) distance of 2.265 Å. This 
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result is consistent with the DFT calculations which show that 3b is more stable than 
3a by 24.09 kJ/mol. 
Similarly, the energies of configurations of [(η5-C5Me5)Ir(phpy)(9-MeA-N1)]
+  
with different orientations of the NH2 group of 9-EtA in adducts of complexes 1 and 2 
were optimized and compared, Table S5. The DFT calculations show that for 
[(η5-C5Me5)Ir(phpy)(9-MeA-N1)]
+ 
(4(N1)), adduct 4(N1)a (NH2 group of 9-EtA on 
the phenyl ring side of the phpy ligand) is more stable than 4(N1)b (NH2 group on the 
pyridine ring side). This preference was confirmed in solution by the 
1
H–1H NOESY 
2D NMR spectrum recorded in MeOD-d4, Figure 5. An NOE cross peak was observed 
between the H2 of bound 9-MeA and the pyridine ring (mixing times 0.15 s to 0.8 s). 
This configuration may be stabilized by a π orbital interaction between N(NH2 of 
adenine)∙∙∙C1/C2 (phpy), Figure 2. The energies of these nucleobase adducts of 
complexes 1 and 2 are compared and listed in Table S5. 
Partition Coefficients (log P). Lipophilicity often correlates with cytotoxic 
potency and has therefore been used extensively in structure-activity correlations.
32
 
The octanol-water partition coefficients (log P) for complexes 1 and 2 were 
determined and are listed in Table 2. Instead of water alone, 0.2 M NaCl was used to 
suppress hydrolysis of the complexes. Complex 1 is positively-charged and shows a 
negative log P value of –0.95 (partitions preferentially into water ca. 10-fold), whilst 
the neutral complex 2 is much more hydrophobic with log P value of 1.57 (partitions 
preferentially into octanol ca. 30-fold), Table 2. The difference in partition coefficient 
between complexes 1 and 2 is thus directly related to their difference in charge. 
The hydrophobicity and cancer cell activity correlate significantly in this study. 
Complex 1 [(η5-C5Me5)Ir(bpy)Cl]
+
 is less hydrophobic and inactive. Complex 2 
[(η5-C5Me5)Ir(phpy)Cl] displays much higher hydrophobicity, and is cytotoxic. This 
hydrophobicity difference is likely to result in higher cancer cell uptake and 
contribute to the higher cytotoxicity of complex 2. 
For compounds in the Comprehensive Medicinal Chemistry (CMC) database, 
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which is often used to validate new pharmacophores, log P values range between –0.4 
and 5.6, with an average value of 2.52.
33
 The log P value of 1.57 for complex 2 is 
within this range, whilst the log P of –0.95 for complex 1 is more negative, i.e. the 
complex 1 may be too hydrophilic for optimum drug-like properties.  
Cytotoxicity. The cytotoxicity of complexes 1
5
 and 2 towards A2780 human 
ovarian cancer cells was investigated, Table 2. The IC50 value (concentration at which 
50% of the cell growth is inhibited) for complex [(η5-C5Me5)Ir(bpy)Cl]
+
 (1) was >100 
μM (and is thus deemed inactive). However, the 2-phenylpyridine complex 2 is 
relatively potent with an IC50 value of 10.8 μM (Table 2), comparable to that of 
carboplatin.
23
 Complex [(η5-C5Me5)Ir(phpy)Cl] (2) appears to be the first reported 
active Ir
III
 anticancer complex with both Cp* and C,N-chelating ligand. The higher 
cancer cell cytotoxicity of complex 2 correlates with its higher hydrophobicity and 
stronger nucleobase binding compared to complex 1. 
Some square-planar Au
III
 complexes containing C,N-chelating phpy ligand have 
been reported to be more cytotoxic than cisplatin in vitro against MOLT-4 human 
leukemia and C2Cl2 mouse tumor cell lines,
11a,34
 although the mechanisms of action 
of these complexes are unknown. 
 
Conclusions  
  The goal of the present study was to design Cp* Ir
III
 complexes which are cytotoxic 
towards cancer cells. Here, we have shown for the first time that Cp* Ir
III
 complex 2 
[(η5-C5Me5)Ir(phpy)Cl] containing C,N-bound 2-phenylpyridine as the chelating 
ligand can exhibit significant cytotoxic activity towards A2780 human ovarian cancer 
cells, in contrast to the inactive analogue complex 1 [(η5-C5Me5)Ir(bpy)Cl]
+
 
containing N,N-bound 2,2′-bipyridine as chelating ligand. Both complexes hydrolyze 
rapidly in water (hydrolysis equilibrium reached within 5 min at 278 K), but aquation 
(substitution of Cl by H2O) is suppressed totally in 104 and 23 mM (extracellular 
concentration) of saline. Complex 2 binds significantly both to 9-EtG and 9-MeA, 
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with a preference for the former, whereas complex 1 binds only to 9-EtG and with 
moderate affinity. The X-ray structure 
[(η5-C5Me5)Ir(phpy)(9-EtG-N7)]NO3·1.5CH2Cl2 (3·NO3·1.5CH2Cl2) appears to be the 
first example of a guanine adduct with a chiral iridium center, and confirms the 
binding of complex 2 to N7 of 9-EtG. No attempt was made to separate the 
enantiomers of 2 or its adducts in the present work. 2D TOCSY, NOESY NMR 
spectroscopy and DFT calculations confirm that complex 2 binds to 9-MeA mainly 
through N1 binding. DFT calculations showed that the NH2 nitrogen of 9-MeA can 
form a π orbital interaction with carbons of the phpy ligand. X-ray crystallography 
and DFT calculations confirm that the adduct [(η5-C5Me5)Ir(phpy)(9-EtG-N7)]
+
 (3b, 
carbonyl group of bound 9-EtG on the pyridine side), and adduct 
[(η5-C5Me5)Ir(phpy)(9-MeA-N1)]
+ 
(4(N1)a, NH2 group of bound 9-EtA on the phenyl 
ring side of phpy ligand) are the most stable 9-EtG and 9-MeA adducts of complex 2, 
respectively. Complex 2 is more hydrophobic than complex 1. The strong nucleobase 
binding ability and higher hydrophobicity of complex 2 may contribute to its lower 
IC50 value.  
This work illustrates how the structure, chemical reactivity and cancer cell 
cytotoxicity of the Cp* Ir
III
 complexes can be controlled by variation of the chelating 
ligands. The promising anticancer activity of the organometallic iridium(III) 
C,N-complex 2 provides a basis for further exploration of this new class of anticancer 
complexes.  
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Contrasting Reactivity and Cancer Cell Cytotoxicity of Isoelectronic 
Organometallic Iridium(III) Complexes 
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Peter J. Sadler* 
 
 
 
 
The structures, hydrolysis, nucleobase binding and hydrophobicity of two 
isoelectronic organometallic iridium(III) cyclopentadienyl complexes are investigated 
with the aim of understanding why only one of them is cytotoxic towards human 
ovarian cancer cells.  
